Voice: More violence comes from domestic terrorists than undocumented immigrants The Ledger © Patrick Semansky, AP FILE - In this March 20, 2021, file photo the U.S. Capitol dome stands past partially-removed razor wire hanging from a security fence on Capitol Hill in Washington. Authorities suggested for weeks in court hearings and papers that members of the Oath Keepers militia group planned their attack on the Capitol in advance in an effort to block the peaceful transition of power. But prosecutors have since said it’s not clear whether the group was targeting the Capitol before Jan. 6, giving defense attorneys an opening to try to sow doubt in the government’s case. (AP Photo/Patrick Semansky, File) ORG XMIT: WX106
Big Rock Partners Acquisition Corp Clarifies Procedure for Stockholder Conversions and Urges Stockholders To Vote For Extension Amendment Proposal
phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.
Big Rock Partners Acquisition Corp Clarifies Procedure for Stockholder Conversions and Urges Stockholders To Vote For Extension Amendment Proposal
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
RADNOR, Pa. and GENEVA, Jan. 11, 2021 /PRNewswire/ NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG (SIX: RLF,OTCQB: RLFTF) ( Relief ), and the Quantum Leap Healthcare Collaborative ( Quantum Leap ) of San Francisco announce that NeuroRx and QLHC have signed a Clinical Trial Participation Agreement for the inclusion of ZYESAMI™ (RLF-100
TM: aviptadil) in the I-SPY COVID-19 Clinical Trial. Quantum Leap is the sponsor of the I-SPY COVID-19 Trial, a platform trial that is assessing multiple drugs for the treatment of patients with Critical COVID-19 who are hospitalized or in intensive care units. ZYESAMI™ will be included as one of the first drugs targeting Respiratory Failure in critically ill COVID-19 patients.